Categories AlphaGraphs, Earnings, Energy

Marathon Oil (MRO) posts wider-than-expected loss in Q1

Marathon Oil Corporation (NYSE: MRO) slipped to a loss in the first quarter of 2020 from a profit last year, due to higher costs and expenses. The bottom line was wider than the analysts’ expectations while the top line exceeded consensus estimates.

Marathon Oil (MRO) Q1 2020 earnings

The US production averaged 340,000 net barrels of oil equivalent per day (boed) for the first quarter of 2020. The company has suspended Q2 completion activity in Eagle Ford and Bakken while suspending all drilling activity in Oklahoma and Northern Delaware. In light of the substantial change to global commodity prices and the macro environment, the company has withdrawn previously provided guidance.

At the revised capital spending budget of $1.3 billion or less, for full-year 2020, the company now expects its underlying US crude oil production to decline by about 8% on a divestiture-adjusted basis, with a similar percentage decline expected for boe production. Underlying International oil production is expected to decline by about 7% on a divestiture-adjusted basis, with a similar percentage decline expected for boe production.

Marathon Oil now expects that Q2 US crude oil and boe production to be down sequentially due to curtailments along with natural decline from reduced activity. Consistent with a focus to continually reduce its cost structure, Marathon Oil expects to capture annualized cash cost reductions of about $350 million relative to its initial 2020 budget.

Past Performance

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top